Poland · Delayed Price · Currency is PLN Bioceltix Statistics
Total Valuation
Bioceltix has a market cap or net worth of PLN 496.39 million. The enterprise value is 466.34 million.
| Market Cap | 496.39M |
| Enterprise Value | 466.34M |
Important Dates
The last earnings date was Thursday, September 18, 2025.
| Earnings Date | Sep 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 19.13% in one year.
| Current Share Class | 4.92M |
| Shares Outstanding | 4.92M |
| Shares Change (YoY) | +19.13% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 22.66% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 15.81 |
| P/TBV Ratio | 15.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -33.32 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -32.97 |
Financial Position
The company has a current ratio of 101.08
| Current Ratio | 101.08 |
| Quick Ratio | 101.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -65.18 |
Financial Efficiency
Return on equity (ROE) is -36.70% and return on invested capital (ROIC) is -23.24%.
| Return on Equity (ROE) | -36.70% |
| Return on Assets (ROA) | -20.29% |
| Return on Invested Capital (ROIC) | -23.24% |
| Return on Capital Employed (ROCE) | -40.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Bioceltix has paid 31,119 in taxes.
| Income Tax | 31,119 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.89% in the last 52 weeks. The beta is 1.26, so Bioceltix's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +48.89% |
| 50-Day Moving Average | 101.81 |
| 200-Day Moving Average | 101.01 |
| Relative Strength Index (RSI) | 49.21 |
| Average Volume (20 Days) | 9,821 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.68M |
| Operating Income | -14.22M |
| Pretax Income | -13.96M |
| Net Income | -14.00M |
| EBITDA | -13.50M |
| EBIT | -14.22M |
| Earnings Per Share (EPS) | -2.84 |
Balance Sheet
The company has 30.05 million in cash and n/a in debt, giving a net cash position of 30.05 million or 6.10 per share.
| Cash & Cash Equivalents | 30.05M |
| Total Debt | n/a |
| Net Cash | 30.05M |
| Net Cash Per Share | 6.10 |
| Equity (Book Value) | 31.39M |
| Book Value Per Share | 6.37 |
| Working Capital | 31.39M |
Cash Flow
In the last 12 months, operating cash flow was -13.34 million and capital expenditures -804,959, giving a free cash flow of -14.14 million.
| Operating Cash Flow | -13.34M |
| Capital Expenditures | -804,959 |
| Free Cash Flow | -14.14M |
| FCF Per Share | -2.87 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioceltix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.13% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.82% |
| FCF Yield | -2.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |